Nature Reviews Gastroenterology & Hepatology 14, 269–278 (2017)
In the version of this Review published online and in print, representation of the target for the drugs ustekinumab, risankizumab and MEDI2070 were not accurate in Figure 3 and should have highlighted that ustekinumab targets IL-12 and IL-23, whereas MEDI2070 and risankizumab both act on IL-23. The error has been corrected for the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nrgastro.2016.208
Rights and permissions
About this article
Cite this article
Neurath, M. Erratum: Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 14, 688 (2017). https://doi.org/10.1038/nrgastro.2017.138
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.138
This article is cited by
-
DHX9 maintains epithelial homeostasis by restraining R-loop-mediated genomic instability in intestinal stem cells
Nature Communications (2024)
-
Identification of diagnostic biomarks and immune cell infiltration in ulcerative colitis
Scientific Reports (2023)
-
Ophiopogonin D Inhibiting Epithelial NF-κB Signaling Pathway Protects Against Experimental Colitis in Mice
Inflammation (2022)
-
Protective Effect of Saffron in Mouse Colitis Models Through Immune Modulation
Digestive Diseases and Sciences (2022)
-
Filgotinib: A Clinical Pharmacology Review
Clinical Pharmacokinetics (2022)
